# A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

> **NCT01106651** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 716 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Antihyperglycemic agent(s)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01106651
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-11
- **Final completion:** 2013-05
- **Target enrollment:** 716 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106651, "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01106651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*